Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Университет им. Давида Бен-Гуриона в Негеве, Израиль, Беэр-Шева 2 ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России, Россия, Ставрополь
Список исп. литературыСкрыть список Литература 1. Беккер РА, Быков ЮВ. Триттико® (тразодон) – уникальный серотонинергический антидепрессант с рядом дополнительных свойств. Психиатрия и психофармакотерапия. 2018;20(3–4):51–62. 2. Морозов ПВ, Беккер РА, Быков ЮВ. О возможной роли некоторых психотропных препаратов в терапии COVID-19 (краткий обзор). Экспериментальная и клиническая фармакология. 2021;84(2): 104–112. 3. Петрова НН, Шагиахметов ФШ, Борукаев РР. Тразодон: грани клинической эффективности. Психиатрия и психофармакотерапия. 2021; 23 (3): 40–46. 4. Akbas EM, Akbas N. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021; 165 (1): 1–7. doi: 10.5507/bp.2021.011. 5. Allnoch L, Beythien G, Leitzen E et al. Vascular Inflammation Is Associated with Loss of Aquaporin 1 Expression on Endothelial Cells and Increased Fluid Leakage in SARS-CoV-2 Infected Golden Syrian Hamsters. Viruses. 2021; 13 (4): 639. doi: 10.3390/v13040639. 6. Anderson G, Reiter RJ. Melatonin: Roles in influenza, Covid-19, and other viral infections. Rev Med Virol. 2020;30(3):e2109. doi: 10.1002/rmv.2109. 7. Barone MU, Ngongo B, Menna-Barreto L. Autism Spectrum Disorder patients may be susceptible to COVID-19 disease due to deficiency in melatonin. Med Hypotheses. 2021;149:110544. doi: 10.1016/j.mehy.2021.110544. 8. Barone MU, Ngongo B, Menna-Barreto L. Sleep-wake cycle impairment adding on the risk for COVID-19 severity in people with diabetes. Sleep Sci. 2020;13(3): 191–194. doi: 10.5935/1984-0063.20200038. 9. Batum M, Kisabay AK, Mavioğlu H. Covid-19 infection-induced neuromyelitis optica: a case report. Int J Neurosci. 2020;1-7. doi: 10.1080/00207454.2020.1860036. 10. Berridge CW, Spencer RC. Differential cognitive actions of norepinephrine a2 and a1 receptor signaling in the prefrontal cortex. Brain Res. 2016;1641(Pt B):189-96. doi: 10.1016/j.brainres.2015.11.024. 11. Bixquert-Jiménez M, Bixquert-Pla L. Antidepressant therapy in functional gastrointestinal disorders. Gastroenterol Hepatol. 2005;28(8):485-492. doi: 10.1157/13079000. 12. Canli T. A model of human endogenous retrovirus (HERV) activation in mental health and illness. Med Hypotheses. 2019;133:109404. doi: 10.1016/j.mehy.2019.109404. 13. Canli T. Reconceptualizing major depressive disorder as an infectious disease. Biol Mood Anxiety Disord. 2014;4:10. doi: 10.1186/2045-5380-4-10. 14. Cardinali DP. Melatonin and healthy aging. Vitam Horm. 2021;115:67-88. doi: 10.1016/bs.vh.2020.12.004. 15. Cardinali DP. Melatonin: Clinical Perspectives in Neurodegeneration. Front Endocrinol. 2019;10:480. doi: 10.3389/fendo.2019.00480. 16. Childs PA, Rodin I, Martin NJ et al. Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. Br J Psychiatry. 1995;166(2):196-8. doi: 10.1192/bjp.166.2.196. 17. Conte С. Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4. Int J Mol Sci. 2021;22(13):7135. doi: 10.3390/ijms22137135. 18. Corrêa DG, de Souza Lima FC, Bezerra DC et al. COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? Mult Scler. 2021;27(6):973-976. doi: 10.1177/1352458520949988. 19. da Silva FR, Guerreiro RC, Andrade HA et al. Does the compromised sleep and circadian disruption of night and shiftworkers make them highly vulnerable to 2019 coronavirus disease (COVID-19)? Chronobiol Int. 2020;37(5):607-617. doi: 10.1080/07420528.2020.1756841. 20. Daniele S, Da Pozzo E, Zappelli E, Martini С. Trazodone treatment protects neuronal-like cells from inflammatory insult by inhibiting NF-κB, p38 and JNK. Cell Signal. 2015;27(8):1609-1629. doi: 10.1016/j.cellsig.2015.04.006. 21. Daniele S, Zappelli E, Martini С. Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes. J Neuroinflammation. 2015;12:225. doi: 10.1186/s12974-015-0446-x. 22. de Almondes KM, Agudelo HM, Jiménez-Correa U. Impact of Sleep Deprivation on Emotional Regulation and the Immune System of Healthcare Workers as a Risk Factor for COVID 19: Practical Recommendations From a Task Force of the Latin American Association of Sleep Psychology. Front Psychol. 2021;12:564227. doi: 10.3389/fpsyg.2021.564227. 23. Del'Guidice T, Lemay F, Lemasson M et al. Stimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation. Neuropsychopharmacology. 2014;39(5):1125-34. doi: 10.1038/npp.2013.313. 24. Deng J, Zhou F, Hou W et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021;1486(1):90-111. doi: 10.1111/nyas.14506. 25. ECNP Poster Session, 2020. Слайды доступны по адресу: https://ecnp33-ecnp.ipostersessions.com/Default.aspx?s=04-55-EA-52-BC-53-38-58-88-82-63-79-68-39-7B-... Доступ проверен 05.12.2021. 26. Garrone B, Magnani M, Pinza M, Polenzani L. Effects of trazodone on neurotransmitter release from rat mossy fibre cerebellar synaptosomes. Eur J Pharmacol. 2000;400(1):35-41. doi: 10.1016/s0014-2999(00)00378-2. 27. Gasbarri A, Pompili A. Serotonergic 5-HT7-receptors and cognition. Rev Neurosci. 2014;25(3):311-23. doi: 10.1515/revneuro-2013-0066. 28. Ghosh R, De K, Roy D et al. A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection. J Neuroimmunol. 2020;350:577439. doi: 10.1016/j.jneuroim.2020.577439. 29. Hablitz LM, Vinitsky HS, Sun Q et al. Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci Adv. 2019;5(2):eaav5447. doi: 10.1126/sciadv.aav5447. 30. Jain A, Lamperti M, Doyle DJ, Lobo FA. Anaesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair. Comment on Br J Anaesth 2021; 127:e32-4. Br J Anaesth. 2021;127(6):e215-e218. doi: 10.1016/j.bja.2021.09.008. 31. Jensen NH, Cremers TI, Sotty F. Therapeutic potential of 5-HT2C receptor ligands. ScientificWorldJournal. 2010;10:1870-85. doi: 10.1100/tsw.2010.180. 32. Jessen NA, Munk AF, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner's Guide. Neurochem Res. 2015;40(12):2583-2599. doi: 10.1007/s11064-015-1581-6. 33. Joseph-Antony LM, Kannan A, Panneerselvam A et al. Could aquaporin modulators be employed as prospective drugs for COVID-19 related pulmonary comorbidity? Med Hypotheses. 2020;143:110201. doi: 10.1016/j.mehy.2020.110201. 34. Kamal M, Omirah MA, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021;75(3):e13746. doi: 10.1111/ijcp.13746. 35. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C-receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. 2009;29(9):1795-809. doi: 10.1111/j.1460-9568.2009.06718.x. 36. Li Y, Zhang J, Wan J, Liu A, Sun J. Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer's disease. Biomed Pharmacother. 2020;132:110887. doi: 10.1016/j.biopha.2020.110887. 37. Louapre C, Maillart E, Papeix С et al. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. Eur J Neurol. 2021;28(10):3461-3466. doi: 10.1111/ene.14612. 38. Masre SF, Jufri NF, Ibrahim FW, Raub SA. Classical and alternative receptors for SARS-CoV-2 therapeutic strategy. Rev Med Virol. 2021;31(5):1-9. doi: 10.1002/rmv.2207. 39. Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res. 2008;195(1):98-102. doi: 10.1016/j.bbr.2008.05.016. 40. Meyer AC, Nieuwenhuis JJ, Kociszewska VJ et al. Dihydropyridine calcium antagonists depress the amplitude of the plasma melatonin cycle in baboons. Life Sci. 1986;39(17):1563-1569. doi: 10.1016/0024-3205(86)90388-7. 41. Millet JK, Jaimes JA, Whittaker GR. Molecular diversity of coronavirus host cell entry receptors. FEMS Microbiol Rev. 2021;45(3): fuaa057. 42. Morera AL, Abreu-Gonzalez P, Henry M, Garcia-Hernandez A. Trazodone hypnotic effect and nocturnal melatonin secretion. J Clin Psychopharmacol. 2009;29(1):97-99. 43. Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R et al. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010;11:204. doi: 10.1186/1471-2474-11-204. 44. Moutal A, Martin LF, Boinon L et al. SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia. Pain. 2021; 162(1):243-252. doi: 10.1097/j.pain.0000000000002097. 45. Murphy PJ, Myers BL, Badia P. Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiol Behav. 1996;59(1):133-139. doi: 10.1016/0031-9384(95)02036-5. 46. Natoli S, Oliveira V, Calabresi P et al. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol. 2020;27(9):1764-1773. doi: 10.1111/ene.14277. 47. Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A-receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005;19(3):235-241. doi: 10.1177/0269881105051526. 48. Ogren SO, Eriksson TM, Elvander-Tottie E et al. The role of 5-HT1A-receptors in learning and memory. Behav Brain Res. 2008;195(1):54-77. doi: 10.1016/j.bbr.2008.02.023. 49. Our World in Data (OWinD). Coronavirus Pandemic (COVID-19) – the data. Доступно по адресу: https://ourworldindata.org/coronavirus-data Доступ проверен 05.12.2021. 50. Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43(7):1027-1031. doi: 10.1007/s40618-020-01276-8. 51. Pruimboom L. SARS-CoV 2; Possible alternative virus receptors and pathophysiological determinants. Med Hypotheses. 2021;146:110368. doi: 10.1016/j.mehy.2020.110368. 52. Rowlands AV, Kloecker DE, Chudasama Y et al. Association of Timing and Balance of Physical Activity and Rest/Sleep With Risk of COVID-19: A UK Biobank Study. Mayo Clin Proc. 2021;96(1):156-164. doi: 10.1016/j.mayocp.2020.10.032. 53. Schreiber S, Backer MM, Herman I et al. The antinociceptive effect of trazodone in mice is mediated through both mu-opioid and serotonergic mechanisms. Behav Brain Res. 2000;114(1-2):51-6. doi: 10.1016/s0166-4328(00)00185-6. 54. Schreiber S, Pick GG. Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep? Med Hypotheses. 2020;136:109501. doi: 10.1016/j.mehy.2019.109501. 55. Selvaraj K, Ravichandran S, Krishnan S et al. Testicular Atrophy and Hypothalamic Pathology in COVID-19: Possibility of the Incidence of Male Infertility and HPG Axis Abnormalities. Reprod Sci. 2021;28(10):2735-2742. doi: 10.1007/s43032-020-00441-x. 56. Shaw VC, Chander G, Puttanna A. Neuromyelitis optica spectrum disorder secondary to COVID-19. Br J Hosp Med. 2020;81(9):1-3. doi: 10.12968/hmed.2020.0401. 57. Simko F, Reiter RJ. Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19? Life Sci. 2020;256:117902. doi: 10.1016/j.lfs.2020.117902. 58. Speer G, Somogyi P. Thyroid complications of SARS and coronavirus disease 2019 (COVID-19). Endocr J. 2021;68(2):129-136. doi: 10.1507/endocrj.EJ20-0443. 59. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press, 2013. 626 p. ISBN 978-1107686465. 60. Stoschitzky K, Sakotnik A, Lercher P et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55(2):111-115. doi: 10.1007/s002280050604. 61. Tomczak A, Han MH. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study. Mult Scler Relat Disord. 2020;45:102347. doi: 10.1016/j.msard.2020.102347. 62. Valencia-Sanchez C, Flanagan EP. COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? Commentary. Mult Scler. 2021;27(6):976-977. doi: 10.1177/1352458520958357. 63. Vlachou M, Siamidi A, Dedeloudi A et al. Pineal hormone melatonin as an adjuvant treatment for COVID-19 (Review). Int J Mol Med. 2021;47(4):47. doi: 10.3892/ijmm.2021.4880. 64. Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017;19(9):63. doi: 10.1007/s11920-017-0816-4. 65. Wostyn P, De Deyn PP. The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy. Med Hypotheses. 2018;118:142-145. doi: 10.1016/j.mehy.2018.07.007. 66. Wostyn P, Van Dam D, Audenaert K, De Deyn PP. Fibromyalgia as a glymphatic overload syndrome. Med Hypotheses. 2018;115:17-18. doi: 10.1016/j.mehy.2018.03.014. 67. Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med Hypotheses. 2021;146:110469. doi: 10.1016/j.mehy.2020.110469. 68. Yesilkaya UH, Balcioglu YH, Sahin S. Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci. 2020;80:72-73. doi: 10.1016/j.jocn. 2020.08.014. 69. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737-754. doi: 10.1080/23744235.2021.1924397.